Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of repurposed antiviral drugs: Lessons from COVID-19
Miguel Ángel Martı́nez
Drug Discovery Today (2022) Vol. 27, Iss. 7, pp. 1954-1960
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Drug repurposing: An effective strategy to accelerate contemporary drug discovery
Peng Zhan, Bin Yu, Liang Ouyang
Drug Discovery Today (2022) Vol. 27, Iss. 7, pp. 1785-1788
Open Access | Times Cited: 39
Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2
Mohamed S. Bekheit, Siva S. Panda, Adel S. Girgis
European Journal of Medicinal Chemistry (2023) Vol. 252, pp. 115292-115292
Open Access | Times Cited: 26
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 9
Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation
Afnan S. Batubara, Ahmed H. Abdelazim, Ahmed A. Almrasy, et al.
BMC Chemistry (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 18
SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations
Roman S. Tumskiy, Anastasiia V. Tumskaia, Iraida Nikolaevna Klochkova, et al.
Computers in Biology and Medicine (2022) Vol. 153, pp. 106449-106449
Open Access | Times Cited: 24
Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment
Haiying Que, Weiqi Hong, Tianxia Lan, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 19
Antiviral activity of singlet oxygen-photogenerating perylene compounds against SARS-CoV-2: Interaction with the viral envelope and photodynamic virion inactivation
Petra Straková, Petr Bednář, Jan Kotouček, et al.
Virus Research (2023) Vol. 334, pp. 199158-199158
Open Access | Times Cited: 12
Analysis of Antiviral Drug Usage in COVID-19 Fatalities: A Retrospective Study
Mohamed Hassan Dehghan, Mahdis Parhizgar, Delaram Fadaee Heydarabadi, et al.
Deleted Journal (2025) Vol. 2, Iss. 1
Open Access
Review and perspective on bioinformatics tools using machine learning and deep learning for predicting antiviral peptides
Nicolás Lefin, Lisandra Herrera-Belén, Jorge G. Farías, et al.
Molecular Diversity (2023) Vol. 28, Iss. 4, pp. 2365-2374
Closed Access | Times Cited: 9
Bias-force guided simulations combined with experimental validations towards GPR17 modulators identification
Sana Kari, Akshaya Murugesan, Thiyagarajan Ramesh, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 160, pp. 114320-114320
Open Access | Times Cited: 8
Recent updates on the biological efficacy of approved drugs and potent synthetic compounds against SARS-CoV-2
Anjani Anjani, Sumit Kumar, Brijesh Rathi, et al.
RSC Advances (2023) Vol. 13, Iss. 6, pp. 3677-3687
Open Access | Times Cited: 8
Exploring nanoselenium to tackle mutated SARS-CoV-2 for efficient COVID-19 management
Avtar Singh, Paramjit Singh, Rajeev Kumar, et al.
Frontiers in Nanotechnology (2022) Vol. 4
Open Access | Times Cited: 13
Unravelling Insights into the Evolution and Management of SARS-CoV-2
Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, Nonkululeko Avril Mbatha, et al.
BioMedInformatics (2024) Vol. 4, Iss. 1, pp. 385-409
Open Access | Times Cited: 2
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders
Priscila Costa Albuquerque, Fábio Zicker, Bruna de Paula Fonseca e Fonseca
Drug Discovery Today (2022) Vol. 27, Iss. 12, pp. 103396-103396
Open Access | Times Cited: 10
Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2
Bobban Subhadra, Ragini Agrawal, Virender Kumar Pal, et al.
Viruses (2023) Vol. 15, Iss. 6, pp. 1299-1299
Open Access | Times Cited: 5
Molecular modeling of lupeol for antiviral activity and cellular effects
Pawi Bawitlung Lalthanpuii, C. Lalrinmawia, B. Lalruatfela, et al.
Journal of Applied Pharmaceutical Science (2023)
Open Access | Times Cited: 5
Identification of Dual Inhibitors Targeting Main Protease (Mpro) and Cathepsin L as Potential Anti-SARS-CoV-2 Agents
Santo Previti, Roberta Ettari, Elsa Calcaterra, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 5, pp. 602-609
Closed Access | Times Cited: 1
Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods
Mir Saleh Hoseininezhad-Namin, Elaheh Rahimpour, Abolghasem Jouyban
Drug Metabolism Reviews (2024) Vol. 56, Iss. 2, pp. 127-144
Closed Access | Times Cited: 1
Revolutionizing Antiviral Drug Discovery: The Emerging Role of Artificial Intelligence
Mahmoud Kandeel, Abdullah I. A. Al-Mubarak, Sameer Alhojaily, et al.
International Journal of Pharmacology (2024) Vol. 20, Iss. 4, pp. 536-546
Closed Access | Times Cited: 1
Effect of Maraviroc and/or Favipiravir plus systemic steroids versus systemic steroids only on the viral load of adults with severe COVID-19: clinical trial
Elba Medina, Ana Laura Sánchez-Sandoval, Eira Valeria Barrón-Palma, et al.
F1000Research (2024) Vol. 13, pp. 180-180
Open Access | Times Cited: 1
Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies
Reham F. Barghash, Donato Gemmati, Ahmed M. Awad, et al.
Molecules (2024) Vol. 29, Iss. 23, pp. 5564-5564
Open Access | Times Cited: 1
COVID-19 related antiviral drugs are less adsorbable on sediment under alkaline and high cation conditions
Xin Xu, Rong Zhu, Yun Zhang, et al.
The Science of The Total Environment (2023) Vol. 883, pp. 163736-163736
Open Access | Times Cited: 3
Drug Repurposing of the Antiviral Drug Acyclovir: New Pharmaceutical Salts
Paulo Nunes, Pedro H. O. Santiago, Cecília C. P. da Silva, et al.
Crystals (2023) Vol. 13, Iss. 5, pp. 782-782
Open Access | Times Cited: 3
Drug discovery through Covid-19 genome sequencing with siamese graph convolutional neural network
Soumen Kumar Pati, Manan Kumar Gupta, Ayan Banerjee, et al.
Multimedia Tools and Applications (2023) Vol. 83, Iss. 1, pp. 61-95
Open Access | Times Cited: 2
Effect of Maraviroc and/or Favipiravir plus systemic steroids versus systemic steroids only on the viral load of adults with severe COVID-19: clinical trial
Elba Medina, Ana Laura Sánchez-Sandoval, Eira Valeria Barrón-Palma, et al.
F1000Research (2024) Vol. 13, pp. 180-180
Open Access
Page 1 - Next Page

Scroll to top